StreetInsider.com News Articles

H.C. Wainwright Starts Odyssey Therapeutics (ODTX) at Buy

Thu, 27 Aug 2026 06:04:14 -0400

H.C. Wainwright analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $44.00.

The analyst comments "A clinical-stage I&I company built around a potential first-in-class oral RIPK2 scaffolding inhibitor. Odyssey Therapeutics is developing precision small molecules and protein therapeutics against upstream immune nodes where multiple inflammatory pathways converge. Lead asset OD-001 is an oral RIPK2 scaffolding inhibitor in Phase 2 development for ulcerative colitis (UC), with additional opportunity in Crohn's disease (CD). Rather than competing at the ATP site as prior kinase-directed programs did, OD-001 binds RIPK2 and blocks its recruitment of

H.C. Wainwright Starts Odyssey Therapeutics (ODTX) at Buy

Thu, 27 Aug 2026 06:04:14 -0400

H.C. Wainwright analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $44.00.

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team will participate in the following upcoming investor conferences in September:

2026 Cantor Global Healthcare Conference
Conference Dates: September 9-11, 2026
Location: New York, NY
Fireside Chat: September 9^th at 8:35AM ET
Morgan Stanley 24th Annual Global Healthcare Conference
Conference Dates: September

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference
Conference Dates: September 9-11, 2026
Location: New York, NY
Fireside Chat: September 9^th at 8:35AM ET
Morgan Stanley 24th Annual Global Healthcare Conference
Conference Dates: September

Odyssey Therapeutics (ODTX) PT Raised to $29 at JPMorgan

Fri, 07 Aug 2026 09:09:16 -0400

JPMorgan analyst Brian Cheng raised the price target on Odyssey Therapeutics (NASDAQ: ODTX) to $29.00 (from $26.00) while maintaining a Overweight rating.

Form 10-Q Odyssey Therapeutics, For: Jun 30

Thu, 06 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26877483.html

Form 10-Q Odyssey Therapeutics, For: Jun 30

Thu, 06 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26877483.html

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.

Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases